Sugi Predict

Sugi Predict / Compounds / SCHEMBL855348

SCHEMBL855348

SCHEMBL855348

Clc1cc(N2CCOCC2)nc(N2CCOCC2)n1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.68
▸ CYP1A2 P05177 1/20 0.68
▸ CYP2D6 P10635 1/20 0.68
▸ KMT2A Q03164 4/20 0.65
▸ NPSR1 Q6W5P4 1/20 0.56
▸ HRH4 Q9H3N8 1/20 0.56
▸ PIK3CA P42336 4/20 0.53
▸ MAP3K12 Q12852 1/20 0.52
▸ RAF1 P04049 1/20 0.50
▸ BRAF P15056 1/20 0.50
▸ THRB P10828 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ MTOR P42345 2/20 0.48
▸ PIK3CB P42338 1/20 0.47
▸ HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19479135 0.95 CYP1A2 (0.62) MAPTCYP1A2CYP2D6KMT2ANPSR1
SCHEMBL13848246 0.91 CASP1 (0.59) MAPTCYP1A2CYP2D6KMT2ANPSR1
SCHEMBL16094661 0.91 MAPT (0.57) MAPTCYP1A2CYP2D6KMT2ANPSR1
SCHEMBL18799427 0.91 CASP1 (0.59) MAPTCYP1A2CYP2D6KMT2ANPSR1
Hydrochloric Acid SCHEMBL28611311 0.89 CASP1 (0.58) MAPTCYP1A2CYP2D6KMT2ANPSR1
Hydrochloric Acid SCHEMBL3997286 0.89 CASP1 (0.58) MAPTCYP1A2CYP2D6KMT2ANPSR1
Hydrochloric Acid SCHEMBL29434911 0.89 CASP1 (0.58) MAPTCYP1A2CYP2D6KMT2ANPSR1
SCHEMBL17673774 0.89 MAPT (0.56) MAPTCYP1A2CYP2D6KMT2ANPSR1
SCHEMBL1617856 0.89 MAPT (0.56) MAPTCYP1A2CYP2D6KMT2ANPSR1
SCHEMBL16037441 0.88 MAPT (0.55) MAPTCYP1A2CYP2D6KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9637468-B2 Process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine NOVARTIS AG (CH) 2017-05-02 — — US claimed
EP-2912030-B1 IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE NOVARTIS AG (CH) 2016-08-31 — — EP claimed
US-20150246897-A1 Process for Manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine NOVARTIS PHARMA AG (CH) 2015-09-03 — — US claimed
EP-2912030-A1 IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE Novartis AG (CH) 2015-09-02 — — EP claimed
WO-2014064058-A1 IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE NOVARTIS AG (CH) 2014-05-01 — — WO claimed
US-12497407-B2 Treatment of skin disorders TORQUR AG (CH) 2025-12-16 — — US disclosed
US-20240382496-A1 TREATMENT OF SKIN LESIONS TORQUR AG (CH) 2024-11-21 — — US disclosed
US-20240343718-A1 TREATMENT OF NEUROLOGICAL DISORDERS TORQUR AG (CH) 2024-10-17 — — US disclosed
US-11918586-B2 Treatment of skin lesions TORQUR AG (CH) 2024-03-05 — — US disclosed
US-11878972-B2 Treatment of neurological disorders TORQUR AG (CH) 2024-01-23 — — US disclosed
CN-109475560-B Treatment of neurological disorders 巴塞尔大学 2023-05-02 — — CN disclosed
CN-109414415-B Treatment of skin lesions 拓客股份有限公司 2023-05-02 — — CN disclosed
EP-0354920-A1 AMINO-9,10-SECOSTEROIDS THE UPJOHN COMPANY (US) 1990-02-21 — — EP disclosed
EP-0293078-A1 Pharmaceutically active amines THE UPJOHN COMPANY (US) 1988-11-30 — — EP disclosed
WO-1988008424-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1988-11-03 — — WO disclosed
WO-1988007527-A1 AMINO-9,10-SECOSTEROIDS THE UPJOHN COMPANY (US) 1988-10-06 — — WO disclosed
EP-0263213-A1 C20 Through C26 amino steroids THE UPJOHN COMPANY (US) 1988-04-13 — — EP disclosed
WO-1987007895-A1 ANDROSTANE-TYPE AND CORTICAL AMINOESTERS THE UPJOHN COMPANY (US) 1987-12-30 — — WO disclosed
EP-0238545-A1 C 20? THROUGH C 26? AMINO STEROIDS. UPJOHN CO (US) 1987-09-30 — — EP disclosed
WO-1987001706-A2 C20 THROUGH C26 AMINO STEROIDS THE UPJOHN COMPANY (US) 1987-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382496-A1 TREATMENT OF SKIN LESIONS C1R, C3AR1, CXCR3 MAPT 2395/4885CYP1A2 303/4885CYP2D6 348/4885
US-20240343718-A1 TREATMENT OF NEUROLOGICAL DISORDERS CHRM2, CHRM1, C1R MAPT 261/4885CYP1A2 136/4885CYP2D6 146/4885
US-11878972-B2 Treatment of neurological disorders CHRM1, CHRM2, C1R MAPT 161/4885CYP1A2 124/4885CYP2D6 65/4885
US-20150246897-A1 Process for Manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine PAH, QDPR, NISCH MAPT 329/4885CYP1A2 133/4885CYP2D6 88/4885
US-12497407-B2 Treatment of skin disorders RXFP3, CCR3, CBR3 MAPT 2061/4885CYP1A2 405/4885CYP2D6 638/4885
US-11918586-B2 Treatment of skin lesions C1R, C3AR1, CXCR3 MAPT 2395/4885CYP1A2 303/4885CYP2D6 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.